Calidi Biotherapeutics (NYSEAMERICAN:CLDI) Shares Down 0.4% – Here’s What Happened

Calidi Biotherapeutics, Inc. (NYSEAMERICAN:CLDI) dropped 0.4% during mid-day trading on Thursday. The company traded as low as $0.8566 and last traded at $0.8701. 23,775 shares changed hands during trading, a decline of 90% from the average daily volume of 227,811 shares. The stock had previously closed at $0.8740.

Calidi Biotherapeutics Stock Down 3.8%

The company has a quick ratio of 1.68, a current ratio of 1.68 and a debt-to-equity ratio of 0.24. The company has a market capitalization of $2.23 million, a price-to-earnings ratio of -0.02 and a beta of 1.33. The business’s 50-day moving average is $1.23 and its 200-day moving average is $2.28.

Calidi Biotherapeutics (NYSEAMERICAN:CLDI) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($2.94) earnings per share for the quarter.

About Calidi Biotherapeutics

Calidi Biotherapeutics, Inc is a clinical-stage biotechnology company developing cell-based immunotherapies designed to treat cancer. The company’s approach uses allogeneic stem cells as delivery vehicles for anti-cancer agents, with the goal of protecting therapeutic payloads in the body and improving their ability to reach and attack solid tumors.

Calidi’s technology platforms include its SuperNova and Shielded Cytokine approaches. Its pipeline has included CLD-101, an investigational neural stem cell-based therapy being developed for solid tumors such as recurrent glioblastoma, as well as additional programs focused on using engineered stem cells to deliver tumor-killing agents and immune-stimulating cytokines.

Headquartered in San Diego, California, Calidi Biotherapeutics conducts its research and clinical development activities primarily in the United States.